PEPFAR's annual planning process is done either at the country (COP) or regional level (ROP).
PEPFAR's programs are implemented through implementing partners who apply for funding based on PEPFAR's published Requests for Applications.
Since 2010, PEPFAR COPs have grouped implementing partners according to an organizational type. We have retroactively applied these classifications to earlier years in the database as well.
Also called "Strategic Areas", these are general areas of HIV programming. Each program area has several corresponding budget codes.
Specific areas of HIV programming. Budget Codes are the lowest level of spending data available.
Expenditure Program Areas track general areas of PEPFAR expenditure.
Subdivisions of Program Areas, these track general higher level sub-classifications of expenditure.
Subdivisions of Major categories, these are the most detailed expenditure data.
Cross-cutting attributions are areas of PEPFAR programming that contribute across several program areas. They contain limited indicative information related to aspects such as human resources, health infrastructure, or key populations programming. However, they represent only a small proportion of the total funds that PEPFAR allocates through the COP process. Additionally, they have changed significantly over the years. As such, analysis and interpretation of these data should be approached carefully. Learn more
PEPFAR sets targets using the Monitoring, Evaluation, and Reporting (MER) System - documentation for which can be found on PEPFAR's website at https://www.pepfar.gov/reports/guidance/. As with most data on this website, the targets here have been extracted from the COP documents. Targets are for the fiscal year following each COP year, such that selecting 2016 will access targets for FY2017. This feature is currently experimental and should be used for exploratory purposes only at present.
Years of mechanism: 2010
The Strengthening Pharmaceutical Systems program mandate is to build capacity within developing countries to effectively manage pharmaceutical systems, successfully implement USAID priority services, and ultimately save lives and protect the public's health by improving access to and use of medicines of assured quality
In FY08, SPS received HIV/AIDS funding in DR Congo for the first time. During initial discussions with the National HIV/AIDS program (PNLS), several priority issues were identified and activities planned and recently initiated. Due to the cross-cutting nature of pharmaceutical management and the existence of field support funding from other funding sources (i.e. malaria, TB, water, and population/RH) SPS support for HIV/AIDS activities is very often integrated with support for other disease areas. Primary HIV/AIDS activities for FY10 will follow from those activities and needs identified together with the PNLS and the pharmacy program and regulatory authority. These activities will include continued capacity building on quantification and rational medicines use for HIV test kits, ARVs and OI medicines. Another critical area is information systems for HIV/AIDS activities related to HIV/AIDS medicines and related commodities as well as program beneficiaries.
The primary target population for SPS technical assistance is the cadre of health care workers involved in the management and dispensing of HIV/AIDS medicines and related commodities in testing sites and treatment centers in DRC. As SPS is mandated to support USAID DRC service delivery implementing partners working in the Kasai Oriental and Occidental, Katanga and South Kivu provinces. SPS will also work in these provinces on HIV/AIDS activities. Additional provinces may include Kinshasa and Bas Congo.
In FY08 and FY09 SPS also received funds from the following sources: malaria, TB, POP/RH, MCH and Water. As previously mentioned, as pharmaceutical management is cross-cutting activities to build capacity and strengthen the DRC pharmaceutical management system at the national, provincial and health zone levels is funded by this combination of funds. Therefore the funds from these other sources are in effect leveraging the HIV/AIDS resources and vice versa. SPS expects to leverage funds in a similar fashion in FY10 and as several of these funding sources are also identified as key priority issues for FY10 we would expect that child survival activities, family planning, malaria and TB would be integrated as wrap around activities. SPS's primary work and assistance is aimed at strengthening the health system through strengthening the pharmaceutical management system and improving the availability of and access to essential medicines, including HIV/AIDS medicines and related commodities, in the targeted health zones and service delivery points. SPS works closely with ministry of health counterparts at all levels to build capacity to improve coordination for pharmaceutical management, improve skills for medicines management, dispensing and reporting, and improve supervision of these aspects for continuous improvement of services.
Cross-cutting areas that will be covered in the SPS HIV/AIDS activities will include human resources for health and potentially construction/renovation if needs are identified for improving storage facilities for pharmaceuticals at the regional, health zone or health facility level. Wraparound programs that will leverage HIV/AIDS funds and vice versa will very likely include child survival activities, family planning, malaria and TB. Activities to strengthen the capacity of DRC MOH pharmaceutical management stakeholders and national programs at the central and provincial levels to improve coordination for pharmaceutical management, improve quantification and supportive supervision of pharmaceutical management will benefit all of the above listed programs as they are applicable for medicines and related commodities of all of the programs. Similarly, technical assistance at the health zone and facility level to strengthen estimation of needs/ordering, management of medicines, reporting and promote rational medicines use will benefit across all programs.
SPS works very closely with MOH counterparts at all levels to build capacity for eventual integration of longer term activities such as coordination for pharmaceutical management, supervision and monitoring and evaluation into MOH annual workplans. Through our provincial representatives SPS will be able to
provide directed technical assistance to MOH, other USAID implementing partners and other stakeholders working in pharmaceutical management at the provincial and health zone levels. All SPS HIV/AIDS activities were developed in collaboration with the PNLS as well as the MOH pharmaceutical management stakeholders (PNAM and DPM) and are in line with the DRC national harmonized procurement plan for HIV/AIDS medicines and laboratory materials.
SPS FY10 HIV/AIDS activities will focus on systems strengthening and capacity building at the national, provincial and health zone and facility levels.
At the national level SPS will work with MOH pharmaceutical management stakeholders and the PNLS to establish a pharmaceutical management coordination mechanism to ensure that all activities and funding (external and internal) are coordinated with respect to HIV/AIDS medicines and related commodities. Additional support will include pharmaceutical legal and policy documents to improve the standardization of pharmaceutical services and governance within the DRC pharmaceutical management system. SPS
will also work, as needed, with the aforementioned parties as well as Global Fund principal recipients and other implementing partners to quantify needs of HIV/AIDS medicines and related commodities. Information systems for pharmaceutical management information will also be a critical area as there is currently a dearth of information related to HIV/AIDS medicines and related commodities in DRC.
At the provincial level SPS will continue to work with the MOH national program (PNLS, PNT etc) representatives as well as the pharmaceutical management representatives at this level to build capacity and improve coordination among the key players at this level. Additional TA will include quantification and rational medicines use as well as pharmaceutical management information systems. SPS will work at this level to establish and integrate regular supportive supervision activities to ensure that pharmaceutical management at the health zone and service delivery point is regularly monitored.
At the health zone and service delivery point (HGR, CS and other facilities providing HIV/AIDS services) SPS will work to build the capacity of health care workers to effectively manage and dispense medicines, including HIV/AIDS related medicines. Quantification, rational medicines use and pharmaceutical management reporting will be primary areas for strengthening at this level as they've been identified as weak points.